SN BioScience Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$9.3M
- Investors
-
24
SN BioScience General Information
Description
Developer of a nano-medicine drug delivery system designed for cancer therapeutics. The company's system utilizes physico chemically ingrated pharmaco metric technology and is related to the physicochemical properties of the drug, the mechanism of delivery, and the indication, enabling clients to improve clinical outcomes.
Contact Information
Website
www.snbioscience.comCorporate Office
- Suite 422-Na, LH Business growth centerNadong, 54 Changup-ro
- Siheung-dong, Pangyo 2nd Techno Valley Business Growth Center, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
Corporate Office
- Suite 422-Na, LH Business growth centerNadong, 54 Changup-ro
- Siheung-dong, Pangyo 2nd Techno Valley Business Growth Center, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
SN BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 07-Apr-2026 | $9.3M | Completed | Clinical Trials - Phase 2 | ||
| 8. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 7. Early Stage VC (Series B) | 01-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Early Stage VC (Series A) | 31-Dec-2018 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 01-Apr-2018 | Completed | Clinical Trials - Phase 2 | |||
| 4. Angel (individual) | 01-Jan-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Accelerator/Incubator | 01-Nov-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 01-Nov-2017 | $580K | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 01-Nov-2017 | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
SN BioScience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SN BioScience Patents
SN BioScience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025258939-A1 | Pharmaceutical composition comprising peptide derivative and albumin | Pending | 12-Jun-2024 | ||
| AU-2024388941-A1 | Nanoparticles comprising sirolimus and albumin, pharmaceutical composition for subcutaneous administration, comprising same, and preparation method therefor | Pending | 29-Nov-2023 | ||
| EP-4817601-A1 | Nanoparticles comprising sirolimus and albumin, pharmaceutical composition for subcutaneous administration, comprising same, and preparation method therefor | Pending | 29-Nov-2023 | ||
| WO-2025116530-A1 | Nanoparticles comprising sirolimus and albumin, pharmaceutical composition for subcutaneous administration, comprising same, and preparation method therefor | Inactive | 29-Nov-2023 | ||
| ES-3074688-T3 | Method for producing albumin-bound taxane nanoparticles with improved stability in maintaining granulometric distribution | Active | 03-Nov-2021 | A61P35/00 |
SN BioScience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SN BioScience Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Centix Ventures | Venture Capital | Minority | ||
| DAYLI Partners | Venture Capital | Minority | ||
| IB Capital (Bahrain) | PE/Buyout | Minority | ||
| NAU IB Capital | PE/Buyout | Minority | ||
| Pioneer Investment | Corporate Venture Capital | Minority |
SN BioScience Investments (1)
SN BioScience’s most recent deal was a Joint Venture with KSI Biologic. The deal was made on 20-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| KSI Biologic | 20-Nov-2023 | Joint Venture | Other Pharmaceuticals and Biotechnology |
SN BioScience FAQs
-
When was SN BioScience founded?
SN BioScience was founded in 2017.
-
Where is SN BioScience headquartered?
SN BioScience is headquartered in Seongnam, South Korea.
-
What is the size of SN BioScience?
SN BioScience has 25 total employees.
-
What industry is SN BioScience in?
SN BioScience’s primary industry is Drug Discovery.
-
Is SN BioScience a private or public company?
SN BioScience is a Private company.
-
What is SN BioScience’s current revenue?
The current revenue for SN BioScience is .
-
How much funding has SN BioScience raised over time?
SN BioScience has raised $27M.
-
Who are SN BioScience’s investors?
Centix Ventures, DAYLI Partners, IB Capital (Bahrain), NAU IB Capital, and Pioneer Investment are 5 of 24 investors who have invested in SN BioScience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
